Corify Care has announced a new publication on its proprietary Global Volumetric Mapping technology in Nature Communications Medicine. The company says this technology represents the first system capable of mapping all four heart chambers at once, providing physicians with a complete, real-time view of arrhythmias “that current solutions cannot deliver”.
“Our research demonstrates that a volumetric approach is essential for true arrhythmia characterisation,” said study lead author Jorge Vicente-Puig (Universitat Autònoma de Barcelona, Barcelona, Spain). “We have moved beyond the mathematical limitations of the past to offer a complete 3D physiological picture.”
According to Corify, while today’s mapping systems analyse the heart one chamber at a time, meaning clinicians have to “infer what they cannot see”, the company’s own system changes that paradigm by mapping the heart’s surface, enabling—”for the first time”—visualisation inside the cardiac walls and the septum. Corify’s system is said to deliver a single-beat, whole-heart map, revealing how arrhythmias move through the heart wall and across chambers, both before and during ablation procedures.
“This is about visibility and confidence,” commented Corify chief executive officer (CEO) Andreu Climent. “We give physicians the full picture upfront, not fragments. A global view means faster decisions, more targeted ablations, and the potential to reduce procedure time and complexity, providing clinical clarity.”
Corify goes on to state that its system uncovers arrhythmia pathways that are often missed with conventional tools, including circuits located deep within the heart wall or spanning multiple chambers—and, by eliminating blind spots, it helps physicians address complex cases with greater efficiency and predictability.
“For the first time, we can non-invasively see the heart as it truly behaves—globally,” added Corify chief medical officer Felipe Atienza. “This has meaningful implications for workflow, outcomes, and scalability in EP [electrophysiology] labs.”
Corify’s Acorys system has gained CE-mark approval and is currently under US Food and Drug Administration (FDA) review to meet regulatory requirements for the US market. The company states that it is also actively advancing integrations with leading catheter navigation platforms to enable a seamless hybrid workflow.
Additionally, Corify will present new clinical data on the application of its Global Volumetric Mapping technology for atrial fibrillation (AF) and ventricular tachycardia (VT) at the 2026 AF symposium (5–7 February, Boston, USA).
